Despite the notable advancements in cancer pharmacotherapy, such as chemotherapy, targeted therapy, and immunotherapy, which have significantly improved patient survival rates, managing the associated ...
Merz Therapeutics, a business of Merz Group and a leader in the field of neurotoxins, today announced that Health Canada approved XEOMIN® (incobotulinumtoxinA) for the treatment of post-stroke lower ...